Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) experienced a significant increase in short interest for the month of December. As of December 31st, the total short interest rose to 3,840,000 shares, indicating an increase of 8.2% compared to the previous total of 3,550,000 shares recorded on December 15th. Currently, with an average trading volume of 463,300 shares, the short-interest ratio stands at 8.3 days.

Aldeyra Therapeutics Price Performance

On Friday, shares of Aldeyra Therapeutics traded up by $0.06, reaching a price of $4.84 in midday trading. The volume of shares traded was 274,810, which is lower than the average trading volume of 370,307. The company has seen a twelve-month low of $2.71 and a high of $6.55. According to recent data, the 50-day simple moving average is $4.94, while the two-hundred day simple moving average is $4.97. In terms of financial ratios, Aldeyra Therapeutics has a current ratio of 6.80, a quick ratio of 6.80, and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics last reported its quarterly earnings on November 7th, where the biotechnology firm announced earnings per share (EPS) of ($0.25), matching analysts' expectations. Analysts predict that the company will report a full-year EPS of -0.92.

Hedge Funds Weigh In On Aldeyra Therapeutics

Various hedge funds and institutional investors have recently altered their positions regarding Aldeyra Therapeutics. For instance, US Bancorp DE acquired a new position during the third quarter valued at approximately $30,000. Paloma Partners Management Co also initiated a stake worth $62,000 in Aldeyra Therapeutics in the same quarter. The Manufacturers Life Insurance Company increased its stake by 14.4%, now holding 21,734 shares worth $72,000 after an addition of 2,729 shares in the last quarter. King Wealth Management Group raised its holdings by 24.5%, owning 13,700 shares valued at $74,000, following the acquisition of 2,700 additional shares. Additionally, BNP Paribas Financial Markets enhanced its position in the company by 253.3%, now holding 14,229 shares valued at $77,000 after acquiring 10,201 shares during the last quarter. It is notable that 59.71% of the company's stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focusing on the development of innovative therapies aimed at improving the lives of patients suffering from immune-mediated diseases. Among its leading compounds, reproxalap and ADX-629, are designed to target reactive aldehyde species (RASP) that are found in elevated levels in ocular and systemic inflammatory conditions, which can lead to increased cytokine release through the activation of various inflammatory mechanisms.

Aldeyra, Therapeutics, Short, Interest, Investors